|
We recently examined FDA Warning Letters and found that 48 of them
contained complaints referring to HPLC. These include quite general
findings as well as very specific points, as the following list of
examples for selected topics shows.
HPLC in Stability Testing:
- Unidentified HPLC peaks found during stability testing were not
identified or evaluated
- No attempt is made to identify or evaluate degradation products
during routine stability testing. The HPLC recorder is turned off as
soon as the analytical peak elutes
- The stability indicating HPLC method used for related substances
testing of a product has not been fully validated in that the linear
range and Limit of Detection/Limit of Quantitation for all known
impurities has not been determined
HPLC - Calibration/Qualification:
- There is no documentation regarding calibration and preventive
maintenance for HPLCs used by QC Chemistry Laboratory
- Procedure for HPLC Calibration Method 013 has no predetermined
acceptance criteria for the autosampler calibration. The autosampler
calibration does not demonstrate that the instrument is capable of
accurately accessing linearity
- The calibration procedure for HPLC systems is inadequate in that it
did not include integrator and detector's linearity, injector's
reproducibility, and accuracy of temperature settings for column
heater and detector
Computer Validation/Part-11 Compliance of HPLC:
- The HPLC computer software, which is used for data acquisition,
calculations, and change control, is not validated in that areas such
as system operations, system maintenance, change control, data back-up
and archival, system security and disaster recovery have not been
evaluated
- Lack of validation data to support the adequacy of the computer
software used to run the HPLC systems
- It was noted during the inspection that there is an option on the
HPLC that allows analysts to delete results after they were processed
Other Findings:
- Assay peaks with shoulders and unresolved peaks were observed on
release and stability for…
- Your firm did not perform the required standard injection bracketing
required for the HPLC method for both assay and content uniformity
- There is no assurance that the laboratory HPLC columns can produce valid, reliable and reproducible results
- There is no data to demonstrate that the in-house HPLC method used
to release…is equivalent to compendial methods
- The method for integrating HPLC peaks of the same product was
inconsistent
Considering that even the Warning Letters contain so many complaints
referring to HPLC procedures, one can infer that the inspection reports
(483s) themselves deal much more frequently with HPLC findings in FDA
inspections.
This topic is the focus of the ECA Conference HPLC
in a GMP-/FDA-regulated Environment taking place in Heidelberg,
Germany, from 12-13 February 2003. The conference picks up many of the
questions arising during FDA inspections, like method validation,
equipment qualification, Part-11 compliance or method transfer.
For a whole day, the ensuing Post Conference Workshop will deal with the validation of chromatography data systems (CDS) in compliance with
the requirements of 21 CFR Part 11.
Author:
Dr Günter Brendelberger
CONCEPT HEIDELBERG
|